SI2236608T1 - Novi peptidi za zdravljenje in preprečevanje motenj, povezanih z imunskim sistemom, vključno zdravljenje in preprečevanje infekcije z moduliranjem prirojene imunosti - Google Patents

Novi peptidi za zdravljenje in preprečevanje motenj, povezanih z imunskim sistemom, vključno zdravljenje in preprečevanje infekcije z moduliranjem prirojene imunosti

Info

Publication number
SI2236608T1
SI2236608T1 SI200632149A SI200632149A SI2236608T1 SI 2236608 T1 SI2236608 T1 SI 2236608T1 SI 200632149 A SI200632149 A SI 200632149A SI 200632149 A SI200632149 A SI 200632149A SI 2236608 T1 SI2236608 T1 SI 2236608T1
Authority
SI
Slovenia
Prior art keywords
treating
preventing
related disorders
innate immunity
novel peptides
Prior art date
Application number
SI200632149A
Other languages
English (en)
Inventor
Oreola Donini
Annett Rozek
Shannon Wayne Lentz
Original Assignee
Soligenix, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Soligenix, Inc. filed Critical Soligenix, Inc.
Publication of SI2236608T1 publication Critical patent/SI2236608T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Pulmonology (AREA)
SI200632149A 2005-10-04 2006-10-04 Novi peptidi za zdravljenje in preprečevanje motenj, povezanih z imunskim sistemom, vključno zdravljenje in preprečevanje infekcije z moduliranjem prirojene imunosti SI2236608T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US72295805P 2005-10-04 2005-10-04
US72295905P 2005-10-04 2005-10-04
US72296205P 2005-10-04 2005-10-04
EP10003191.3A EP2236608B1 (en) 2005-10-04 2006-10-04 Novel peptides for treating and preventing immune-related disorders, including treating and preventing infection by modulating innate immunity

Publications (1)

Publication Number Publication Date
SI2236608T1 true SI2236608T1 (sl) 2017-03-31

Family

ID=37905947

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200632149A SI2236608T1 (sl) 2005-10-04 2006-10-04 Novi peptidi za zdravljenje in preprečevanje motenj, povezanih z imunskim sistemom, vključno zdravljenje in preprečevanje infekcije z moduliranjem prirojene imunosti

Country Status (22)

Country Link
US (2) US8124721B2 (sl)
EP (6) EP2447368A3 (sl)
JP (2) JP2009509552A (sl)
KR (1) KR101410685B1 (sl)
CN (1) CN101351554B (sl)
AU (1) AU2006299682B2 (sl)
BR (1) BRPI0616936B8 (sl)
CA (1) CA2625183C (sl)
CY (1) CY1118840T1 (sl)
DK (2) DK2447367T3 (sl)
ES (1) ES2609520T3 (sl)
HK (1) HK1128728A1 (sl)
HU (1) HUE031989T2 (sl)
IL (1) IL190601A (sl)
LT (1) LT2236608T (sl)
MX (1) MX2009003636A (sl)
MY (1) MY157947A (sl)
PL (1) PL2236608T3 (sl)
PT (1) PT2236608T (sl)
RU (2) RU2507213C2 (sl)
SI (1) SI2236608T1 (sl)
WO (1) WO2007038876A1 (sl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2447368A3 (en) * 2005-10-04 2012-12-26 Inimex Pharmaceuticals Inc. Novel peptides for treating and preventing immune-related disorders, including treating and preventing infection by modulating innate immunity
AU2007304847A1 (en) * 2006-10-04 2008-04-10 Inimex Pharmaceuticals, Inc. Novel peptides for treating and preventing immune-related disorders, including treating and preventing infection by modulating innate immunity
US10227384B2 (en) * 2013-04-12 2019-03-12 Yale University Modified proteins and methods of use thereof
HRP20231652T1 (hr) 2013-09-13 2024-05-10 Soligenix, Inc. Peptidi za primjenu u liječenju oralnog mukozitisa
US11311598B2 (en) * 2013-09-13 2022-04-26 Soligenix, Inc. Peptides and analogs for use in the treatment of oral mucositis
US20150148304A1 (en) * 2013-10-24 2015-05-28 Soligenix, Inc. Novel Peptides and Analogs for Use in the Treatment of Macrophage Activation Syndrome
CN108602880A (zh) * 2015-10-16 2018-09-28 阿尔萨尼斯生物科学有限责任公司 肺炎克雷伯氏菌的杀菌性单克隆抗体
WO2018165764A1 (en) * 2017-03-16 2018-09-20 Microsintesis Inc. Compositions and methods involving probiotic molecules
WO2024038888A1 (ja) * 2022-08-19 2024-02-22 森永乳業株式会社 組成物

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO812612L (no) 1980-08-06 1982-02-08 Ferring Pharma Ltd Enzym-inhibitorer.
ATE211654T1 (de) 1992-09-16 2002-01-15 Univ Tennessee Res Corp Antigene des hybriden m-proteins und träger für gruppe a streptokokkenimpfstoff
US5916872A (en) * 1996-07-24 1999-06-29 Intrabiotics Pharmaceuticals, Inc. Cyclic peptides having broad spectrum antimicrobial activity
US20030176357A1 (en) * 1998-10-06 2003-09-18 Pospisilik Andrew J. Dipeptidyl peptidase IV inhibitors and their uses for lowering blood pressure levels
US7504490B1 (en) * 1998-10-16 2009-03-17 Oscient Pharmaceuticals Corporation Nucleic acid and amino acid sequences relating to Apergillus fumigatus for diagnostics and therapeutics
EP2275551B1 (en) * 1999-10-29 2015-04-08 Novartis Vaccines and Diagnostics S.r.l. Neisserial antigenic peptides
GB9929464D0 (en) * 1999-12-13 2000-02-09 Proteom Ltd Complementary peptide ligande generated from the human genome
IL134830A0 (en) 2000-03-01 2001-05-20 Chay 13 Medical Res Group N V Peptides and immunostimulatory and anti-bacterial pharmaceutical compositions containing them
US20090062512A1 (en) * 2000-10-10 2009-03-05 Hildebrand William H Comparative ligand mapping from MHC class I positive cells
FR2825095B1 (fr) * 2001-05-28 2003-09-26 Dev Des Antigenes Combinatoire Dispositif de presentation de polypeptides, utilisable comme "puce" pour la detection miniaturisee de molecules
JP2004531731A (ja) 2001-05-31 2004-10-14 ザ トラスティーズ オブ プリンストン ユニバーシテイ Ｉａｐ結合ペプチドおよびｉａｐに結合する化合物を同定するアッセイ
US20030130199A1 (en) * 2001-06-27 2003-07-10 Von Hoersten Stephan Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents
US7368421B2 (en) * 2001-06-27 2008-05-06 Probiodrug Ag Use of dipeptidyl peptidase IV inhibitors in the treatment of multiple sclerosis
WO2003002595A2 (en) 2001-06-27 2003-01-09 Probiodrug Ag Dipeptidyl peptidase iv inhibitors and their uses as anti-cancer agents
GB0125445D0 (en) * 2001-10-23 2001-12-12 Ferring Bv Protease Inhibitors
AU2002365675B2 (en) * 2001-12-03 2007-04-05 The University Of British Columbia Effectors of innate immunity
US7507787B2 (en) * 2001-12-03 2009-03-24 The University Of British Columbia Effectors of innate immunity
EP1575479A4 (en) 2002-01-31 2006-10-25 Develogen Israel Ltd HSP-PEPTIDES AND ANALOGUES FOR MODULATING IMMUNE RESPONSES ON ANY PRESENTING CELLS
US8535672B2 (en) * 2002-04-04 2013-09-17 Yissum Research Development Of The Hebrew University Of Jerusalem Broad-spectrum in-vivo effective superantigen toxin antagonists based on the interaction between CD28 and the superantigen and uses thereof
US7618788B2 (en) * 2002-05-10 2009-11-17 Millipore Corporation Proteome epitope tags and methods of use thereof in protein modification analysis
SE0201863D0 (en) 2002-06-18 2002-06-18 Cepep Ab Cell penetrating peptides
US20040037809A1 (en) 2002-06-28 2004-02-26 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of interferon beta
CA2500715A1 (en) 2002-10-03 2004-04-15 Epimmune, Inc. Hla binding peptides and their uses
CN1878791A (zh) 2003-09-12 2006-12-13 诺和酶股份有限公司 合成的抗微生物多肽
WO2005038000A2 (en) * 2003-10-17 2005-04-28 Pecos Labs, Inc. T cell epitopes useful in mycobacterium tuberculosis vaccine and as diagnostic tools and methods for identifying same
EA200601575A1 (ru) * 2004-03-01 2007-06-29 Пептера Фармасьютикалс Лтд. Казеиновые пептиды и их терапевтическое применение
WO2006038208A2 (en) 2004-07-12 2006-04-13 Medical Research Fund Of Tel Aviv Sourasky Medical Center Agents capable of downregulating an msf-a - dependent hif-1α and use thereof in cancer treatment
WO2006005190A1 (en) * 2004-07-14 2006-01-19 Inimex Pharmaceuticals Inc. Method of screening for protection from microbial infection
EP1626059A1 (en) 2004-08-09 2006-02-15 Institut National De La Sante Et De La Recherche Medicale (Inserm) Angiogenic and immunologic applications of anti-CD160 specific compounds obtainable from mAb CL1-R2
CA2629751A1 (en) 2004-11-12 2006-05-18 The University Of British Columbia Antimicrobial peptides
US20090180958A1 (en) 2005-04-26 2009-07-16 Karyon-Ctt Ltd. Diagnostic and therapeutic agents
EP2447368A3 (en) * 2005-10-04 2012-12-26 Inimex Pharmaceuticals Inc. Novel peptides for treating and preventing immune-related disorders, including treating and preventing infection by modulating innate immunity
AU2007304847A1 (en) * 2006-10-04 2008-04-10 Inimex Pharmaceuticals, Inc. Novel peptides for treating and preventing immune-related disorders, including treating and preventing infection by modulating innate immunity

Also Published As

Publication number Publication date
AU2006299682B2 (en) 2013-09-05
RU2009117490A (ru) 2010-11-10
PT2236608T (pt) 2017-03-01
CY1118840T1 (el) 2018-01-10
KR20080070814A (ko) 2008-07-31
JP5780600B2 (ja) 2015-09-16
BRPI0616936B1 (pt) 2021-02-02
PL2236608T3 (pl) 2017-06-30
EP2447369A2 (en) 2012-05-02
EP2447367A3 (en) 2013-01-02
JP2009509552A (ja) 2009-03-12
JP2012223199A (ja) 2012-11-15
EP2236608A3 (en) 2010-12-29
MX2009003636A (es) 2009-04-22
DK2447367T3 (en) 2019-02-18
MY157947A (en) 2016-08-30
IL190601A (en) 2014-08-31
CA2625183A1 (en) 2007-04-12
US8124721B2 (en) 2012-02-28
EP2447367A2 (en) 2012-05-02
BRPI0616936A2 (pt) 2011-07-05
DK2236608T3 (en) 2017-02-20
EP2076596A4 (en) 2010-07-21
RU2008115390A (ru) 2009-11-10
AU2006299682A1 (en) 2007-04-12
EP1931779A4 (en) 2009-07-29
LT2236608T (lt) 2017-03-27
EP2447369A3 (en) 2012-09-05
RU2507213C2 (ru) 2014-02-20
US9416157B2 (en) 2016-08-16
EP2236608A2 (en) 2010-10-06
EP2236608B1 (en) 2016-12-07
WO2007038876A1 (en) 2007-04-12
HUE031989T2 (en) 2017-08-28
BRPI0616936B8 (pt) 2021-05-25
US20090246217A1 (en) 2009-10-01
EP2447367B1 (en) 2018-12-05
US20130224231A1 (en) 2013-08-29
EP2447368A3 (en) 2012-12-26
KR101410685B1 (ko) 2014-06-24
EP2076596A1 (en) 2009-07-08
HK1128728A1 (zh) 2009-11-06
EP2447368A2 (en) 2012-05-02
IL190601A0 (en) 2008-11-03
CN101351554B (zh) 2016-05-18
ES2609520T3 (es) 2017-04-20
EP1931779A1 (en) 2008-06-18
CA2625183C (en) 2019-09-03
CN101351554A (zh) 2009-01-21

Similar Documents

Publication Publication Date Title
HK1128728A1 (zh) 包括通過調節先天免疫治療和預防感染在內的治療和預防免疫相關疾病的新型肽
IL210538A0 (en) Novel peptides for treating and preventing immune-related disorders, including treating and preventing infection by modulating innate immunuity
PL380828A1 (pl) Fosfoniany, amidomonofosfoniany, amidobisfosfoniany do leczenia chorób wirusowych
GB2397297B (en) Improved bottle stopper
IL177490A0 (en) Methods for the treatment of tinnitus induced by cochlear excitotoxicity
HK1161702A1 (en) Air treatment system
GB0710529D0 (en) Vaccine
IL186895A0 (en) Methods for treating eye conditions
EP1912667A4 (en) CONCENTRATED PROTEIN LYOPHILISATES, ASSOCIATED METHODS AND USES THEREOF
EP1912698A4 (en) OPHTHALMIC INJECTOR SYSTEM
IL188788A0 (en) Treatment of conditions associated with the presence of macromolecular aggregates, particularly ophthalmic disorders
EP1723238A4 (en) MODIFIED ONCOLYTIC VIRUSES
EP1871793A4 (en) PROTOONCOGEN HUMAN AND PROTEIN CODED THEREWITH
HK1125305A1 (en) Methods for treating viral infections using polyamine analogs
IL208070A0 (en) Myxoma virus mutants for therapeutic treatment
EP1962970A4 (en) REHABILITATION TREATMENT SUSPENSION DEVICE
WO2007103584A3 (en) Polyamides for treating human papilloma virus
HK1142342A1 (en) Cyclic, cystein-free protein
EP1709991A4 (en) ELECTRODE FOR PROCESSING AND TREATMENT DEVICE
GB2440089B8 (en) Regeneration system, its production and use
EP1942909A4 (en) METHODS OF TREATING RESPIRATORY DISORDERS
EP1872794A4 (en) NASAL VACCINE
ZA200803284B (en) Novel peptides for treating and preventing immune-related disorders, including treating and preventing infection by modulating innate immunity
GB2430370B (en) Chinese medicine preparation for treating AIDS
EP1644020A4 (en) LYASE TREATMENT FOR P. CARINII